An analysis of kidney biopsies before and after obinutuzumab treatment of lupus nephritis showed histologic remission or near remission in a greater proportion of patients than had complete renal ...
Treating lupus nephritis to achieve sustained remission for at least 3 years likely protects kidney function. In patients with active lupus nephritis, at least 3 years of sustained clinical remission ...
When added to standard care, more lupus nephritis patients achieved complete remissions with obinutuzumab (Gazyva) than with placebo. Treatment was added to mycophenolate mofetil and glucocorticoids.
Please provide your email address to receive an email when new articles are posted on . Time spent in clinical remission had an inverse correlation with kidney damage accrual. The shortest period of ...
And altogether, what we want to achieve is that the patient who has experienced a very significant lupus activity, a flare, a very persistent or, or a sudden increase, that we will get them to be in ...
All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response (PERR); first patient to reach 1-year follow-up ...
Eventual tapering and withdrawal of steroids in patients with lupus nephritis is recommended to minimize the drugs' adverse effects, but the ideal timing is uncertain. This study followed 136 lupus ...
Fate Therapeutics announced positive clinical results for its off-the-shelf CAR T-cell program, FT819, in treating moderate-to-severe systemic lupus erythematosus (SLE) at the EULAR 2025 Congress. All ...
There is no set definition or timeframe for what counts as lupus remission. It’s no wonder lupus remission is a confusing topic! This month, Dr. Ronald van Vollenhoven, director of Amsterdam ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results